EUVIMEDEUVIMED entdecken
Crossref

Serum urate, cardiovascular mediators, and atrial fibrillation: genetic evidence for URAT1-targeted therapy

Chaoyang Lin, Qianyao Lai, Enze Fang, Ben Luo, Zhiwei Chen, Jinhua Huang, Feng Hu, Enhui Yao

Clinical Rheumatology · 2026

DOI: 10.1007/s10067-025-07827-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2026. Verfasst von Chaoyang Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medical Center, Fujian Institute of Coronary Artery Disease…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Uric Acid, Organic Anion Transporters, Organic Cation Transport Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Medical Innovation Project of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Current evidence indicates that high serum urate levels are associated with an increased occurrence of atrial fibrillation (AF), and urate-lowering drugs could potentially reduce this risk. Nonetheless, the processes driving this relationship remain unclear. OBJECTIVE: To identify key mediators linking urate to AF and assess the direct effects of potential drug targets on AF risk. METHODS: Genetic variants associated with serum urate levels, potential mediators, and urate-lowering drug targets were identified from genome-wide association studies (GWAS). Univariable Mendelian randomization, multivariable Mendelian randomization, and two-step-cis-MR were conducted. The Bayesian horseshoe prior MR approach was used as the primary method, and Genomic SEM was employed to support the mediation model. RESULTS: The study identified a genetic and causal relationship between serum urate levels and AF onset. Key mediators included systolic blood pressure (proportion mediated 56.23%), diastolic blood pressure (25.27%), hypertension (49.46%), hypercholesterolemia (4.83%), coronary atherosclerosis (12.24%), myocardial infarction (30.32%), coronary artery disease (29.74%), and heart failure (47.66%). Drug target MR analysis found strong evidence for URAT1 inhibition reducing AF risk (odds ratio [OR] = 0.91, 95% Bayesian credible interval [BCI] 0.85 to 0.97; Bayesian posterior probability [BPP] = 0.997), which persisted after mediator adjustment. Under stricter flanking regions, evidence weakened after adjustment for heart failure (OR = 0.93, 95% BCI 0.84 to 1.04; BPP = 0.907) but remained robust for other mediators. CONCLUSION: This study highlights several cardiovascular conditions (hypertension, hypercholesterolemia, heart failure, coronary artery diseases) as key mediators between serum urate and AF and supports URAT1 inhibition as a potential therapeutic strategy. Key points •Elevated serum urate increases the risk of atrial fibrillation, potentially through cardiovascular mediators such as hypertension, heart failure, and coronary artery diseases. •Genetic evidence from drug-target Mendelian randomization supports URAT1 inhibition as a potential therapeutic strategy for reducing atrial fibrillation risk. •The protective effect of URAT1 inhibition against atrial fibrillation persists after adjusting for key cardiovascular mediators, suggesting additional therapeutic pathways beyond those identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationUric AcidOrganic Anion TransportersOrganic Cation Transport ProteinsHumansGenome-Wide Association StudyMendelian Randomization AnalysisPolymorphism, Single NucleotideBayes TheoremHypertensionBlood PressureCoronary Artery Disease

Stichwörter der Autor:innen

Atrial fibrillationDrug targetMediation analysisMendelian randomizationURAT1-targeted therapyUrate

Substanzen

Uric AcidOrganic Anion TransportersOrganic Cation Transport ProteinsSLC22A12 protein, human

Autor:innen und Institutionen

  • Department of Cardiology, Fujian Medical University Union Hospital, Fujian Cardiovascular Medical Center, Fujian Institute of Coronary Artery Disease, Fujian Cardiovascular Research Center, Fuzhou, 350001, People's Repu…
  • School of Health, Fujian Medical University, Fuzhou, People's Republic of China.

Förderung

  • Medical Innovation Project of Fujian Province

Zitieren

APA

Lin, C., Lai, Q., Fang, E., Luo, B., Chen, Z., Huang, J., Hu, F., & Yao, E. (2026). Serum urate, cardiovascular mediators, and atrial fibrillation: genetic evidence for URAT1-targeted therapy. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07827-9

Vancouver

Lin C, Lai Q, Fang E, Luo B, Chen Z, Huang J, et al. Serum urate, cardiovascular mediators, and atrial fibrillation: genetic evidence for URAT1-targeted therapy. Clinical Rheumatology. 2026. doi:10.1007/s10067-025-07827-9

BibTeX
@article{Lin2026,
  author = {Lin, Chaoyang and Lai, Qianyao and Fang, Enze and Luo, Ben and Chen, Zhiwei and Huang, Jinhua and Hu, Feng and Yao, Enhui},
  title = {Serum urate, cardiovascular mediators, and atrial fibrillation: genetic evidence for URAT1-targeted therapy},
  journal = {Clinical Rheumatology},
  year = {2026},
  doi = {10.1007/s10067-025-07827-9}
}
Kostenlos starten →